Marieke Pierik

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

Mirthe E. van der Valk, Marie‐Josée J. Mangen, Max Leenders et al. · Gut · 2012 · 491 citations · Full text

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

Geert D’Haens, Séverine Vermeire, Guy Lambrecht et al. · Gastroenterology · 2018 · 295 citations · Full text

Inflammation, Chronic Inflammatory Diseases, Infliximab Dose +8

Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease

Nicholas T. Ventham, Nicholas A. Kennedy, Alex Adams et al. · Nature Communications · 2016 · 264 citations · Full text

Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)

Pieter Dewint, Bettina E. Hansen, Elke Verhey et al. · Gut · 2013 · 258 citations · Full text

Fatigue and health-related quality of life in inflammatory bowel disease

Mariëlle Romberg‐Camps, Yvonne Bol, Pieter C. Dagnelie et al. · Inflammatory Bowel Diseases · 2010 · 239 citations